Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151515 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
A Phase 3 study of Androgenetic Alopecia, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide.
- Completed
- Registry status
- Phase 3
- Development phase
- 352
- Enrollment target
- 15
- Study locations
NCT00151515: Completed Phase 3 study of Androgenetic Alopecia, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide.
NCT00151515 is a Phase 3 study of Androgenetic Alopecia that has completed, run by Johnson & Johnson Consumer and Personal Products Worldwide. The registered enrollment target is 352 participants, above the 143-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (146% higher). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00151515, a Phase 3 study of Androgenetic Alopecia, has completed, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 352 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
Conditions Studied
Interventions
- DRUG minoxidil
Study Locations (15)
California
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - Vallejo
Minnesota
- Pfizer Investigational Site - Fridley
- Pfizer Investigational Site - Minneapolis
Ohio
- Pfizer Investigational Site - Cincinnati
- Pfizer Investigational Site - Cleveland
Texas
- Pfizer Investigational Site - Austin
- Pfizer Investigational Site - Dallas
Colorado
- Pfizer Investigational Site - Denver
Connecticut
- Pfizer Investigational Site - New Haven
North Carolina
- Pfizer Investigational Site - Durham
Oregon
- Pfizer Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
What the finished NCT00151515 record still lists
NCT00151515 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, above the 143-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (146% higher).
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which minoxidil is the first listed.
NCT00151515 lists 15 locations in 10 states (California, Minnesota, Ohio).
Frequently Asked Questions
What is clinical trial NCT00151515 about?
NCT00151515 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss". The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair l...
What is the current status of trial NCT00151515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 352 participants. The study started on 2003-10. Estimated completion is 2004-07.
What conditions does trial NCT00151515 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT00151515?
The interventions under investigation include: minoxidil (DRUG).
Who is sponsoring clinical trial NCT00151515?
This trial is sponsored by Johnson & Johnson Consumer and Personal Products Worldwide, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00151515 being conducted?
This trial has 15 study locations across California, Colorado, Connecticut, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00151515's enrollment target sits among peer trials
352 4th of 16 higher than 13 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
RECRUITING · Phase 3
-
Safety and Efficacy of VDPHL01 in Males With AGA
ACTIVE NOT RECRUITING · Phase 3
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
Safety and Efficacy of VDPHL01 in Males and Females With AGA
ACTIVE NOT RECRUITING · Phase 2
-
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia